446 related articles for article (PubMed ID: 12834116)
41. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
Holzer SE; Ludlow CL
Laryngoscope; 1996 Jan; 106(1 Pt 1):86-92. PubMed ID: 8544635
[TBL] [Abstract][Full Text] [Related]
42. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
[TBL] [Abstract][Full Text] [Related]
43. The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients.
Patel AB; Bansberg SF; Adler CH; Lott DG; Crujido L
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):859-63. PubMed ID: 26024910
[TBL] [Abstract][Full Text] [Related]
44. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
Dharia I; Bielamowicz S
Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
[TBL] [Abstract][Full Text] [Related]
45. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
[TBL] [Abstract][Full Text] [Related]
46. Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction.
Schönweiler R; Wohlfarth K; Dengler R; Ptok M
Laryngoscope; 1998 Jan; 108(1 Pt 1):55-63. PubMed ID: 9432068
[TBL] [Abstract][Full Text] [Related]
47. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia.
Bielamowicz S; Stager SV; Badillo A; Godlewski A
J Voice; 2002 Mar; 16(1):117-23. PubMed ID: 12002878
[TBL] [Abstract][Full Text] [Related]
48. Singer's dystonia: first report of a variant of spasmodic dysphonia.
Chitkara A; Meyer T; Keidar A; Blitzer A
Ann Otol Rhinol Laryngol; 2006 Feb; 115(2):89-92. PubMed ID: 16514788
[TBL] [Abstract][Full Text] [Related]
49. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia.
Koriwchak MJ; Netterville JL; Snowden T; Courey M; Ossoff RH
Laryngoscope; 1996 Dec; 106(12 Pt 1):1476-81. PubMed ID: 8948606
[TBL] [Abstract][Full Text] [Related]
50. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
French G; Bosch JD; Randall DR
J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
[TBL] [Abstract][Full Text] [Related]
51. Spasmodic dysphonia combined with insufficient glottic closure by phonation.
Kaszás Z; Lichtenberger G; Mészáros K; Falvai J
Eur Arch Otorhinolaryngol; 2003 Sep; 260(8):418-20. PubMed ID: 12709812
[TBL] [Abstract][Full Text] [Related]
52. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
53. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
Bielamowicz S; Ludlow CL
Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573
[TBL] [Abstract][Full Text] [Related]
54. Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique.
Young N; Blitzer A
Laryngoscope; 2007 Nov; 117(11):2082-4. PubMed ID: 17828055
[TBL] [Abstract][Full Text] [Related]
55. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
56. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
57. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia.
Chang CY; Chabot P; Thomas JP
Otolaryngol Head Neck Surg; 2007 Jun; 136(6):894-9. PubMed ID: 17547976
[TBL] [Abstract][Full Text] [Related]
58. Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin.
Dejonckere PH; Neumann KJ; Moerman MB; Martens JP; Giordano A; Manfredi C
Eur Arch Otorhinolaryngol; 2012 Apr; 269(4):1195-203. PubMed ID: 22210475
[TBL] [Abstract][Full Text] [Related]
59. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia.
Ludlow CL; Naunton RF; Sedory SE; Schulz GM; Hallett M
Neurology; 1988 Aug; 38(8):1220-5. PubMed ID: 3399071
[TBL] [Abstract][Full Text] [Related]
60. A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S.
Chang CY; Chabot P; Walz CM
Ear Nose Throat J; 2009 May; 88(5):E18. PubMed ID: 19444777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
